Hope you are right though Pudding. Right now we are just implementing a system to just report the cases.

https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html 

has a small section on investigational theraputics


Edit - Looks like Trump has been watching Tucker Carlson. I so hope it's true..... hes just floated out so many other inaccuracies on this its hard to believe. Please be right. (faith and hope is an odd thing)

I'm not particularly impressed.
But then again, I've never understood the use of Z-paks for viral infections. The idea that they're including that makes me suspicious. I'm sure someone with medical training (danm maybe) can explain it, but antibiotics don't work on viruses themselves. Maybe an opportunistic infection or something... but it simply doesn't kill a virus.

The idea that they're combining it with Z-paks makes me think they're just throwing the kitchen sink at it.

The idea of using HIV drugs sounds way more promising. Stop the viruses ability to reproduce in our cells... but those are pretty expensive.

.
Look at the last chart in the PDF, it's the last thing in the entire document, right at the bottom of the last page.

Note that "patients with PCR-positive samples" on the vertical axis essentially means "patients with detectable COVID-19 still in their bodies".

That chart says it all. Look at that green line!
.

Despite the common wisdom that "antibiotics aren't effective against viruses", in this case it's not entirely true. Quoting the last paragraph on page 12 of the PDF:

"Azithromycin has been shown to be active in vitro against Zika and Ebola viruses and to prevent severe respiratory tract infections when administrated to patients suffering viral infection"

The last part of that quote refers to the "opportunistic infections" you mentioned, but the first part is what I'm referring to. It actually kills Zika and Ebola (and possibly other virii), at least in vitro. I'm not sure anyone has proven it in vivo yet though.


No, it's pretty well-thought out, it's just that most laymen (and many doctors!) are still completely unaware of azithromycin's anti-viral properties. It's not been widely publicized.

As I said above, look at the last chart at the bottom of the last page in that PDF file. The difference between Hydroxychloroquine alone and Hydroxychloroquine plus azithromycin is very large and impressive. Only the combination of the two seems to reach "cure" status.


It was just announced yesterday that a pair of HIV drugs had no discernible effect on COVID-19. Others may though! Lots of stuff is being tried right now!
.

.
Annnnnnnnnd Trump's going to authorize widespread use of it against COVID-19 "almost immediately", awesome!

https://www.foxnews.com/politics/trump-fda-experimental-drugs-coronavirus 

izonfire, there's your major media confirmation, and presidential confirmation too! Of wide rollout at least, if not confirmation of effectiveness yet.

Let's hope the "100% cure" results of the study hold in the wider population! We're about to find out!
.

I dunno about z packs anti viral efficacy or not (truly don't know, not saying either way) but it would still make sense in terms of treatment.... ie the secondary infections

Hope so. I also remember 4 million tests by a couple fridays ago and an imminent vax. But I truly hope so and hope it works. Unfortunately I still need to act as if it wont.

You sure know alot about infections and stuff... 😟

This study was conducted in southern France by one of the world's top infectious disease researchers, not in China.

China merely reported early success with this same drug, that led the French team to try it.


Yup. Be cautiously happy about this, but ACT as if it doesn't exist, for now anyway.

Hope for the best, but keep planning for the worst, for the moment. Very wise.
.

more about bacterial than viral.

Interesting. I dug a little into the research papers leading up to that. Seems like it inhibits viral replication. The Zika papers focused on it because that particular antibiotic can move into the amniotic fluid/and gather in fetal brain tissue at concentrations they were looking for. The tests themselves are all in cell culture, obviously, and none of them discuss the mechanism at which it might block viral replication (there are other referenced papers of the referenced papers if I want to dig back far enough, but I'm out of time). It's interesting. May actually do something.

Give this a couple days, maybe a week to see if it works... and then split my 457 money 50/50 fixed / moderately aggressive?

The market has to rebound... especially if this ends sooner than expected.

I agree on the rebound. Prolly not to where it was for quite awhile since it was inflated anyway. I am an optimist although I may not always show it.

Oh, it'll rebound all right.... I suspect like a rocket.

In the meantime, if you're auto-reinvesting dividends (company DRIP or, far better nowadays, broker DRIP) you're getting AWESOMELY CHEAP additional shares which is great!

If a stock you hold is $50/share and it crashes to $25/share, that means every quarter when it gives you its dividend and your broker auto-reinvests it, you'll get DOUBLE the number of shares you would've had the crash never occurred.

When this crisis is over, you'll still have all those extra shares, forever! And of course, they will throw off dividends of their own, which will turn into more shares that do the same, making your "snowball" of compounding wealth ever-larger.

As long as you don't sell when prices are in the crapper and you instead buy (either by DRIP or manually), this coronavirus crisis will likely end up being a good thing in the long-term, believe it or not.
.

No matter what happens on this "cure" we blew it. Time is important and we were flat footed despite all the warnings. If not this one the next but all take time to some degree. We are doing what we are doing based on what we expect in days or weeks rather than months.

I wouldn't spike the ball just yet

This was just updated yesterday which is an eternity LOL I pulled this from a system commonly used for treatment protocols that is updated daily. This is just a snippet.


Investigational agents — A number of investigational agents are being explored for antiviral treatment of COVID-19, and enrollment in clinical trials should be discussed with patients or their proxies. A registry of international clinical trials can be found on the WHO website and at clinicaltrials.gov.

Certain investigational agents have been described in observational series or are being used anecdotally based on in vitro or extrapolated evidence. It is important to acknowledge that there are no controlled data supporting the use of any of these agents, and their efficacy for COVID-19 is unknown.

●Remdesivir – Several randomized trials are underway to evaluate the efficacy of remdesivir for moderate or severe COVID-19 [74]. Remdesivir is a novel nucleotide analogue that has activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and related coronaviruses (including SARS and MERS-CoV) both in vitro and in animal studies [75,76]. The compassionate use of remdesivir through an investigational new drug application was described in a case report of one of the first patients with COVID-19 in the United States [77]. Any clinical impact of remdesivir on COVID-19 remains unknown.

●Chloroquine/hydroxychloroquine – Both chloroquine and hydroxychloroquine inhibit SARS-CoV-2 in vitro, although hydroxychloroquine appears to have more potent antiviral activity [78]. A number of clinical trials are underway in China to evaluate the use of chloroquine or hydroxychloroquine for COVID-19 [79].

●Lopinavir-ritonavir – This combined protease inhibitor, which has primarily been used for HIV infection, has in vitro activity against the SARS-CoV [80] and appears to have some activity against MERS-CoV in animal studies [81]. The use of this agent for treatment of COVID-19 has been described in case reports [82-84], but its efficacy is unclear. In one report of five patients who were treated with lopinavir-ritonavir, three improved and two had clinical deterioration; four had gastrointestinal side effects. It is being evaluated in larger randomized trials.

●Tocilizumab – Treatment guidelines from China's National Health Commission include the IL-6 inhibitor tocilizumab for patients with severe COVID-19 and elevated IL-6 levels; the agent is being evaluated in a clinical trial [85].

Other interventions of interest but with limited or no clinical data include interferon beta and convalescent serum.



The studies referenced for hydoxychloroquine are

Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020.

I'm not sure how they compare to what was mentioned above. Anecdotal data is dangerous but not unuseful Haven't had time to take a close look at either. Interesting though.


Any or either of these could be fast tracked by the FDA (compassionate use) which would make sense.

You used bullets and bigger words than above... 😟

Im sorry

FDA Commissioner, in the exact same presser basically said even with these fast-tracking known drugs we're looking at months until it's an approved treatment.

(this won't necessarily stop use... but it will certainly impact things)